வீரம் வாழ்க்கை அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வீரம் வாழ்க்கை அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வீரம் வாழ்க்கை அறிவியல் Today - Breaking & Trending Today

JenaValve Technology Receives CE Mark for its Trilogy™ TAVI


JenaValve Technology Receives CE Mark for its Trilogy™ TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis
May 25, 2021 08:00 ET
| Source:
JenaValve Technology, Inc.
JenaValve Technology, Inc.
Irvine, California, UNITED STATES
IRVINE, Calif., May 25, 2021 (GLOBE NEWSWIRE) JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its Trilogy
TM Heart Valve System for the treatment of both aortic regurgitation (AR), also known as aortic insufficiency (AI), and aortic stenosis (AS). ....

United States , Stephan Baldus , John Kilcoyne , Hendrik Treede , Gimv Euronext , Bain Capital Life Sciences , Valiance Life Sciences , University Hospital Mainz , Jenavalve Technology Inc , Valve Technology , Valve System , Trilogy Heart Valve System , Trilogy System , Jenavalve Trilogy System , Transcatheter Heart Valve , Transfemoral Delivery , Heart Center Department , University Hospital Cologne , Trilogy Valve System , Cardiovascular Surgery , Cormorant Asset Management , Andera Partners , Edmond De Rothschild Investment Partners , Legend Capital , Neomed Management , Jenavalve Technology ,

JenaValve Technology Receives CE Mark for its Trilogy TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

IRVINE, Calif., May 25, 2021 JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease, today announced that it has received CE Mark for its Trilogy™ Heart Valve System for the treatment of both aortic regurgitation (AR), also known as aortic insufficiency (AI), and aortic stenosis (AS). ....

United States , Stephan Baldus , John Kilcoyne , Hendrik Treede , Gimv Euronext , Bain Capital Life Sciences , Valiance Life Sciences , University Hospital Mainz , Jenavalve Technology Inc , Jenavalve Technology , Heart Valve System , Trilogy Heart Valve System , Trilogy System , Jenavalve Trilogy System , Transcatheter Heart Valve , Transfemoral Delivery , Heart Center Department , University Hospital Cologne , Trilogy Valve System , Cardiovascular Surgery , Valve Technology , Cormorant Asset Management , Andera Partners , Edmond De Rothschild Investment Partners , Legend Capital , Neomed Management ,